Browse May's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.
Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.
With rituximab-treated patients having an elevated risk for severe COVID-19 and a reduced likelihood of responding to vaccines, Sebastian Sattui and David Jayne discuss how these challenges can be addressed and explore the future role of the drug for the treatment of rheumatic diseases (13:17).
Zachary Wallace discusses the changes that have occurred in rheumatology practice as a result of the COVID-19 pandemic, and explores what lessons can be taken forward to improve patient care.
Findings from the CoronavRheum trial suggest that suspension of methotrexate for 2 weeks after each dose of the Sinovac inactivated SARS-CoV-2 vaccine may improve antibody response rates to vaccination among people with rheumatoid arthritis.
Measuring IL-22 levels may help predict whether IL-17 inhibitors or TNF inhibitors are more suitable for patients with psoriatic arthritis, Japanese research suggests.
Individuals with gout and concurrent chronic kidney disease are no more likely to die following allopurinol initiation, dose escalation, or achievement of target serum urate levels than those not taking the drug, study findings indicate.
Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.
Gene expression profiles are associated with rituximab response among people of African or Asian ancestry with systemic lupus erythematosus, but not in those of European ancestry, research suggests.